Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Same active ingredient as Wegovy injections, working with your bodys natural appetite signals
The oral segment is expected to grow rapidly with CAGR of 22.9% during the forecast period due to its convenience and noninvasive administration, which improves patient observation
Discontinuation rates actually favor Retatrutide at 11.2% compared to higher rates for some oral options
A third strategic pattern is format differentiation, with the oral Wegovy launch in the United States and the Wegovy MD multi-dose pen launch in Japan showing that the semaglutide weight management drug market is rewarding companies that tailor route and device choices to different patient and system needs
US$ 22.05
US$ 24.43
US$ 28.52
US$ 26.33
US$ 29.71
US$ 21.78
